Nucleotide and oligonucleotide prodrugs

Details Nucleotide and oligonucleotide prodrugs Nucleotide and oligonucleotide prodrugs

2006-12-12

2011-12-13

McIntosh, III, Traviss C (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S04400A, C514S048000, C514S052000, C536S022100, C536S026100

Reexamination Certificate

active

08076303

ABSTRACT:
The present invention discloses compounds of formula (I):which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of anti-HBV treatment. The invention also relates to methods of treating a HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

REFERENCES:
patent: 5142051 (1992-08-01), Holy et al.
patent: 5641763 (1997-06-01), Holy et al.
patent: 5770713 (1998-06-01), Imbach et al.
patent: 6881831 (2005-04-01), Iyer et al.
patent: 7256179 (2007-08-01), Iyer et al.
patent: 98/07734 (1998-02-01), None
patent: WO98/07734 (1998-02-01), None
Iyer, Radhakrishnan P., et al., “Nucleotide analogs as novel anti-hepatitis B virus agents,” Current Opinion in Pharmacol., 5: 520-528 (2005).
Iyer, Radhakrishnan P., et al., “Phosphorothioate Di- and Trinucleotides as a Novel Class of Anti-Hepatitis B Virus Agents,” Antimicrob. Agents and Chemotherapy, 48: 2199-2205 (2004).
Iyer, Radhakrishnan P., et al., “Anti-Hepatitis B Virus Activity of ORI-9020, a Novel Phosphorothioate Dinucleotide, in a Transgenic Mouse Model,” Antimicrob. Agents and Chemotherapy, 48: 2318-2320 (2004).
Bundgaard, H., “Design of Bioreversible Drug Derivatives and the Utility of the Double Prodrug Concept,” in Bio-reversible carriers in drug design (Ch. 2). Theory and Application. Roche, E.B. Ed.; Pergamon Press: New York, 1987; pp. 13-94.
Oliyai, R. and Stella, V. J., “Prodrugs of Peptides and Proteins for Improved Formulation and Delivery,” Annu. Rev Pharmacol. Toxicol., 32: 521-544 (1993).
Papot, S., et al., “Design of Selectively Activated Anticancer Prodrugs: Elimination and Cyclization Strategies,” Curr. Med. Chem., 2: 155-185 (2002).
Hayat, S., et al., “An Alternative Method for the Highly Selective Iodination of Alcohols Using a Csl/BF3.Et2O System,” Synth. Commun., 33(14): 2531-2540 (2003).
Fernández, I., et al., “A Simple Convenient Procedure for the Synthesis of Formate Esters and Alkyl Iodides from Alcohols Using the System Thionyl Chloride-Dimethylformamide-Alkaline Iodide,” Synlett, 489-490 (1993).

Affiliated with

Also associated with

Rating

Nucleotide and oligonucleotide prodrugs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleotide and oligonucleotide prodrugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleotide and oligonucleotide prodrugs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4300069